Artivion(US:AORT)2026-02-12 21:10Financial Performance - GAAP revenue for Q4 2025 was $116.0 million, up from $97.3 million in Q4 2024, while full year GAAP revenue reached $441.3 million compared to $388.5 million in 2024[3]. - Adjusted revenue for Q4 2025 was $118.3 million, reflecting an 18% increase on an adjusted constant currency basis compared to Q4 2024, and full year adjusted revenue was $443.6 million, a 13% increase[3]. - GAAP net income for Q4 2025 was $2.4 million, or $0.05 per fully diluted share, compared to a net loss of $(16.5) million, or $(0.39) per fully diluted share in Q4 2024; full year net income was $9.8 million versus a net loss of $(13.4) million in 2024[3][8]. - Non-GAAP net income for Q4 2025 was $8.6 million, or $0.17 per fully diluted share, compared to $0.2 million, or $0.00 per fully diluted share in Q4 2024; full year non-GAAP net income was $29.7 million compared to $10.8 million in 2024[7][8]. - Adjusted EBITDA for Q4 2025 increased 29% to $22.7 million from $17.6 million in Q4 2024, and for the full year, adjusted EBITDA rose 26% to $89.6 million[3][5]. - Total revenues for the year ended December 31, 2025, increased to $441.33 million, up 13.5% from $388.54 million in 2024[29]. - Net income for the year ended December 31, 2025, was $9.77 million, compared to a net loss of $13.36 million in 2024[29]. - Total revenues for the three months ended December 31, 2025, were $118.305 million, an 18% increase from $99.840 million in the prior year[32]. - Adjusted EBITDA for the three months ended December 31, 2025, was $22.722 million, compared to $17.606 million in the same period of 2024[34]. - Adjusted net income for the year ended December 31, 2025, reached $29,741 million, compared to $10,768 million in 2024, reflecting a year-over-year increase of approximately 175%[36]. Revenue Growth - Stent grafts revenue grew by 44%, On-X by 25%, and preservation services by 6% in Q4 2025 compared to Q4 2024, driving overall revenue growth[5]. - North America contributed $221.742 million to total revenues for the year, a 12% increase from $197.724 million in the prior year[31]. - Aortic stent grafts generated $43.343 million in revenue for the three months ended December 31, 2025, up 36% from $31.987 million in the prior year[31]. - On-X products saw a revenue increase of 24%, reaching $27.797 million compared to $22.474 million in the previous year[31]. Future Projections - Artivion expects 2026 revenues to be between $486 million and $504 million, representing a growth of 10% to 14% on an adjusted constant currency basis compared to 2025[9]. - The company anticipates adjusted EBITDA growth of 18% to 22% for 2026, resulting in an expected range of $105 million to $110 million[9]. Expenses and Costs - Operating income for the year ended December 31, 2025, was $33.75 million, a decrease of 13.5% from $38.87 million in 2024[29]. - Research and development expenses for the year ended December 31, 2025, were $30.99 million, up from $28.45 million in 2024, indicating a growth of 8.9%[29]. - General, administrative, and marketing expenses for the three months ended December 31, 2025, were $56.841 million, up from $51.429 million in the prior year[34]. - The company incurred $3,484 million in amortization expenses for the three months ended December 31, 2025, down from $4,205 million in the same period of 2024[36]. - Business development, integration, and severance costs amounted to $5,151 million for the three months ended December 31, 2025, compared to $5,821 million in 2024[36]. Balance Sheet and Cash Flow - Cash and cash equivalents at the end of 2025 increased to $64.91 million, up from $53.46 million at the end of 2024[27]. - Total current assets rose to $358.08 million in 2025, compared to $290.08 million in 2024, reflecting a growth of 23.4%[23]. - Total liabilities decreased to $436.56 million in 2025 from $512.90 million in 2024, a reduction of 15.0%[25]. - The company’s total stockholders' equity increased to $448.23 million in 2025, up from $276.20 million in 2024, reflecting a growth of 62.2%[25]. - Free cash flows for the year ended December 31, 2025, were $839 thousand, a decrease from $11.048 million in 2024[34]. Clinical and Regulatory Developments - Positive clinical data from Endospan's NEXUS TRIOMPHE IDE trial showed 94% patient survival and 91% free from disabling stroke at one year post-treatment[6]. - The company filed the fourth and final module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prothesis[3]. Other Notable Events - The company experienced a cybersecurity incident with a net impact of $(2,880) million for the three months ended December 31, 2025, compared to a positive recovery of $4,583 million in the same period of 2024[36]. - The tax expense calculated at a 25% tax rate for adjusted income was $2,858 million for the three months ended December 31, 2025, compared to $66 million in 2024[36].